CU Anschutz conducted a clinical trial that found GLP-1 medications can help reduce alcohol consumption. Dr. Joseph Schacht led the study. The trial tested semaglutide, a drug used for diabetes and weight loss, to see if it could help heavy drinkers cut down.
The study was reported by 9News. The findings suggest that GLP-1s may be a useful tool for treating alcohol use disorder. The research adds to growing evidence that medications used for other conditions can be repurposed for addiction treatment.
Sources: 9News (Denver TV station)
